Aptar Pharma is a worldwide manufacturer of drug delivery systems for nasal applications.
The installation of a manufacturing plant for its Child Resistant and Senior Friendly Classic Nasal Pump in New York (NY) represents an important step in the history of Aptar Pharma, bringing its manufacturing capacity closer to the target market for which this pump has been successfully established.
Aptar Pharma’s child resistant technology platform was developed primarily for the US market, in response to the US Consumer Product Safety Commission (CPSC) rule.
The ruling requires child resistant packaging for any drug product containing the equivalent of 0.08 milligrams or more of imidazoline (16 CFR Part 1700.14), a formulation widely used in nasal decongestant topical sprays.
Less than 2 years after the announcement of the rule, Aptar Pharma introduced its newly engineered Child Resistant and Senior Friendly Classic Nasal Spray Pump to the US market, which successfully matched the CPSC requirements.
Now all major brands of nasal decongestant topical sprays in the US come with Aptar Pharma’s child resistant feature.
Alex Theodorakis, President of Aptar Pharma North America, said: “We are pleased to welcome the arrival of Aptar Pharma’s child resistant assembly machine to our recently expanded Congers, NY manufacturing site.
"This added manufacturing capacity enables us to offer the production of this key child resistant/senior friendly feature to our customers domestically. Being closer to our customers continues to be of strategic importance to Aptar Pharma, and this new initiative enables us to continue to support our important North American marketplace and increase our demand reactivity.”